Skip to main content

View full-text article in PMC

. 2014 Sep 26;9(9):e107988. doi: 10.1371/journal.pone.0107988

Table 2. Univariable analyses of standard clinical variables and galectin mRNA expression levels in relation to overall survival in 87 patients with early stage NSCLC.

	HR	95% CI	p-value
Age	1.03	1.00 to 1.06	0.064
Gender	0.71	0.37 to 1.40	0.325
Stage^a	1.91	1.09 to 3.35	0.024
Histology^b	0.76	0.44 to 1.33	0.340
Smoking status^c	1.30	0.70 to 2.42	0.402
Gal1^d	1.94	1.10 to 3.41	0.022
Gal3^d	0.60	0.34 to 1.05	0.071
Gal4^d	0.68	0.39 to 1.18	0.170
Gal7^d	0.96	0.53 to 1.74	0.899
Gal8^d	0.78	0.45 to 1.36	0.383
Gal9^d	0.76	0.44 to 1.33	0.333
Gal9FL^d	0.54	0.30 to 0.99	0.045
Gal9d5^d	0.48	0.26 to 0.87	0.016
Gal9d56^d	0.73	0.41 to 1.32	0.304

^a)

Stage I vs. stage II, ^b)Squamous vs. others, ^c)Former smoker vs. others, ^d)Above vs. below median mRNA expression